Array BioPharma and Amgen Partner in Type 2 Diabetes

Array BioPharma Inc. and Amgen Inc. announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with type 2 diabetes. Amgen will pay $60 million up-front with additional potential milestones and royalties payments to Array.
The glucokinase (GK) activator ARRY-403 is a member of a new class of drugs targeting type 2 diabetes. Activating GK with small molecules such as ARRY-403 lowers blood glucose levels by enhancing the ability of the pancreas to sense glucose, which leads to increased insulin production. Simultaneously, glucokinase activators increase the net uptake of blood glucose by the liver.

ASweetLife Team

Abbott and Tandem Partner to Combine FreeStyle Libre with… Abbott and Tandem Diabetes Care announced that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's continuous glucose monitoring (CGM) technology with Tandem's insulin delivery systems…
New Study Shows Covid-19 Risk Higher in Type 2 Diabetes than… A new study of people with diabetes hospitalized with COVID-19 has found that Type 1 diabetes may be significantly less dangerous than Type 2 diabetes. The paper, titled “Type 1…
Type 2 Diabetes and COVID-19: What We Know Now Our early understanding of the novel coronavirus, and the CDC recommendations that have largely driven American policy and behavior, were based almost entirely on the first reports to trickle out…
The Latest Numbers on COVID-19 and Type 1 Diabetes In late May, we wrote about the first studies to explicitly analyze the health outcomes of people with Type 1 diabetes during the coronavirus pandemic. At the time, the two…
Insulin Treatment is Associated with Increased Mortality in… A new study in Cell Metabolism has suggested that patients with COVID-19 and Type 2 diabetes that received insulin treatments were significantly more likely to die than those that did…